CN Patent

CN112543771B — 抗b7h3抗体-依喜替康类似物偶联物及其医药用途

Assigned to Changzhou Hengbang Pharmaceutical Co ltd · Expires 2023-04-11 · 3y expired

What this patent protects

本发明披露了抗B7H3抗体‑依喜替康类似物偶联物、其制备方法，以及其抗肿瘤的医药用途。

USPTO Abstract

本发明披露了抗B7H3抗体‑依喜替康类似物偶联物、其制备方法，以及其抗肿瘤的医药用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112543771B
Jurisdiction
CN
Classification
—
Expires
2023-04-11
Drug substance claim
No
Drug product claim
No
Assignee
Changzhou Hengbang Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.